🇺🇸 FDA
Pipeline program

Claseprubart

DNTH103-CIDP-301

Phase 3 small_molecule active

Quick answer

Claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy is a Phase 3 program (small_molecule) at Dianthus Therapeutics, Inc. /DE/ with 1 ClinicalTrials.gov record(s).

Program details

Company
Dianthus Therapeutics, Inc. /DE/
Indication
Chronic Inflammatory Demyelinating Polyneuropathy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials